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Abstract
Background: Calorie restriction (CR) prevents obesity and exerts anticancer effects in many preclinical models.
CR is also increasingly being used in cancer patients as a sensitizing strategy prior to chemotherapy regimens.
While the beneficial effects of CR are widely accepted, the mechanisms through which CR affects tumor growth are
incompletely understood. In many cell types, CR and other nutrient stressors can induce autophagy, which provides
energy and metabolic substrates critical for cancer cell survival. We hypothesized that limiting extracellular and
intracellular substrate availability by combining CR with autophagy inhibition would reduce tumor growth more
effectively than either treatment alone.
Results: A 30 % CR diet, relative to control diet, in nude mice resulted in significant decreases in body fat, blood
glucose, and serum insulin, insulin-like growth factor-1, and leptin levels concurrent with increased adiponectin
levels. In a xenograft model in nude mice involving H-RasG12V-transformed immortal baby mouse kidney epithelial
cells with (Atg5+/+) and without (Atg5−/−) autophagic capacity, the CR diet (relative to control diet) genetically
induced autophagy inhibition and their combination, each reduced tumor development and growth. Final tumor
volume was greatest for Atg5+/+ tumors in control-fed mice, intermediate for Atg5+/+ tumors in CR-fed mice and
Atg5−/− tumors in control-fed mice, and lowest for Atg5−/− tumors in CR mice. In Atg5+/+ tumors, autophagic flux
was increased in CR-fed relative to control-fed mice, suggesting that the prosurvival effects of autophagy induction
may mitigate the tumor suppressive effects of CR. Metabolomic analyses of CR-fed, relative to control-fed, nude
mice showed significant decreases in circulating glucose and amino acids and significant increases in ketones,
indicating CR induced negative energy balance. Combining glucose deprivation with autophagy deficiency in
Atg5−/− cells resulted in significantly reduced in vitro colony formation relative to glucose deprivation or
autophagy deficiency alone.
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Conclusions: Combined restriction of extracellular (via CR in vivo or glucose deprivation in vitro) and
intracellular (via autophagy inhibition) sources of energy and nutrients suppresses Ras-driven tumor growth
more effectively than either CR or autophagy deficiency alone. Interventions targeting both systemic energy
balance and tumor-cell intrinsic autophagy may represent a novel and effective anticancer strategy.
Keywords: Calorie restriction, Autophagy, Metabolomics, Nutrient stress, Cancer
Abbreviations: CR, Calorie restriction; ATG5, Autophagy-related protein 5; IGF-1, Insulin-like growth factor 1;
iBMK, Immortalized baby mouse kidney epithelial cells; LC3, Microtubule-associated protein1 light chain 3;
AMPK/mTOR, AMP-activated protein kinase/mammalian target of rapamycin; OCT, Optimal cutting temperature
compound; RIPA, Radioimmunoprecipitation; DAB, Diaminobenzidine; MRS, Magnetic resonance spectroscopy;
PCA, Principal component analysis; pFDR, Positive false discovery rate
Background
Calorie restriction (CR), a nutritionally replete dietary
regimen that reduces calorie intake without incurring
malnutrition, extends lifespan in species from yeast to
mammals, and in rodents delays the onset of multiple
age-associated diseases, including cancer [1–8]. CR im-
proves health and survival in rhesus monkeys, including
decreased risks of diabetes, neurodegeneration, and can-
cer [9–12]. Though it is not yet known whether CR can
extend lifespan in humans, CR improves markers of
cardiovascular aging and skeletal decline, and decreases
inflammatory and endocrine markers typically associated
with age-related diseases such as cancer [13–18], sug-
gesting that the beneficial effects of CR on metabolism
and chronic disease risk in rodent and primate models
may also extend to humans. In addition, CR can repro-
gram several cancer-related signaling pathways and
increase the susceptibility of some cancer cells to che-
motherapeutic agents [19, 20].
CR redirects metabolic investment from cellular repli-
cation toward maintenance and survival [19, 20]. Many
of the beneficial effects of CR may be attributed to sig-
naling through the AMP-activated protein kinase/
mammalian target of rapamycin (AMPK/mTOR) axis
[19, 20]. This system integrates intracellular and
extracellular signals and enables cells to adapt to environ-
mental changes, such as nutrient or growth factor avail-
ability. Activation of mTOR promotes cell survival,
proliferation, and protein translation pathways. In low
nutrient conditions, AMPK acts as a molecular sensor
activating fatty acid oxidation and glucose uptake, inhibit-
ing mTOR signaling, and regulating synthesis of proteins,
lipids, glycogen, and nucleotides. Many cancers can hijack
mTOR/AMPK signaling to promote their growth in chan-
ging external circumstances [21]. CR suppresses mTOR
and increases AMPK activity in many tissues and organs
[22]. A key target of the AMPK/mTOR pathway is macro-
autophagy (hereafter referred to as autophagy), an evolu-
tionarily conserved, tightly controlled pathway in which
proteins, macronutrients, and organelles are sequestered
in double-membraned vesicles and lysosomally de-
graded. Autophagy is a homeostatic process, providing
a conduit for clearance of damaged organelles and ag-
gregated proteins. Autophagy can also function to pro-
mote cell survival during times of nutrient deprivation,
as digested molecules can be recycled to provide energy
and metabolic precursors until external nutrients are
replenished [23]. Autophagy is inhibited by mTOR acti-
vation, while AMPK induces autophagy during low nu-
trient availability [24].
The role of autophagy in cancer is complex and
likely context-dependent. Autophagy can be tumor
suppressive, in particular during tumor initiation [25],
and is regulated by several oncogenes including Myc,
Akt, PI3-kinase, and Ras [26]. Oncogenic mutations in
Ras are known to induce autophagy, and many Ras-
driven tumors are dependent on autophagy [27–29],
likely to provide an ancillary source of energy to rap-
idly proliferating cancer cells. In established tumors,
autophagy induction can be prosurvival, allowing can-
cer cells to overcome nutrient deprivation, hypoxic
conditions, oxidative and metabolic stress, and even
chemotherapy [27, 30, 31].
The anti-aging effects of CR in Caenorhabditis ele-
gans are dependent on autophagy [32], though the
interaction between CR and autophagy in mammals is
less clear [33], and manipulation of autophagy in
combination with CR on tumor development has not
been previously investigated. We hypothesized that
limiting extracellular and intracellular substrate
availability by combining CR with autophagy inhib-
ition would reduce in vivo tumor growth more
effectively than either treatment alone. Using an H-
Ras-transformed xenograft tumor model, we show
here that CR (in association with a metabolic shift
away from glucose utilization and toward fatty acid
oxidation) and autophagy deficiency each suppresses
tumor growth. Moreover, combining CR with autoph-
agy deficiency further reduces tumor growth relative
to either intervention alone.
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Methods
Cell lines
Immortalized baby mouse kidney epithelial cells (iBMK)
were derived from Atg5+/+ or Atg5−/− mice and main-
tained as described previously [28, 33, 34]. Briefly, iBMK
cells were immortalized by E1A and dominant-negative
p53 expression. iBMK cells were then stably transfected
with a H-RasG12V expression construct, and a p-tFl-RFP-
tandem tagged microtubule-associated protein1 light
chain 3 (LC3) expression plasmid [28]. Cells were cul-
tured in DMEM (GIBCO/Invitrogen) supplemented with
10 % fetal bovine serum (FBS), and 1 % penicillin/
streptomycin (Sigma-Aldrich) at 38.5 °C with 8.5 % CO2.
For colony formation assay, 500 cells were seeded in
triplicate into each well of a six-well plate and incubated
for 10 days in DMEM containing 1, 5, or 10 mM glu-
cose. Colonies were fixed for 5 min with 100 % methanol
and stained with 0.5 % crystal violet in 50 % methanol.
Mice, diets, and experimental design
All mouse experimentation was conducted in the Ani-
mal Resource Center at the University of Texas at
Austin in accordance with the recommendations out-
lined in the Guide for the Care and Use of Laboratory
Animals set forth by the National Institutes of Health.
All experimentation was approved by the Institutional
Animal Care and Usage Committee at the University of
Texas at Austin. All efforts were taken to minimize ani-
mal suffering.
Female athymic nude mice (4–6 weeks of age; n = 94)
were singly housed and randomly selected to receive one
of the following diets (n = 47/diet group): (1) control diet
consumed ad libitum (#D12450B, a modified AIN-76A
semipurified diet with 10 kcal% fat) that generates an
overweight phenotype or (2) 30 % calorie-restricted diet
(CR, #D0302702) consumed in daily aliquots that gener-
ate a lean phenotype. The CR diet is based on the control
diet but modified such that when fed as a daily aliquot
provides 70 % of the total caloric intake but 100 % of all
vitamins, minerals, fatty acids, and amino acids. Both diets
were from Research Diets (New Brunswick, NJ).
Following 16 weeks on either control or CR diet, a
subset of mice (n = 19/diet group) were fasted for 6 h,
anesthetized with CO2, and whole blood was collected
by cardiac puncture for fasting glucose assessment and
to obtain serum samples for circulating hormone and
growth factor analysis. Mice were subsequently killed by
cervical dislocation. Blood was allowed to coagulate
(30 min at room temperature), centrifuged at 9300×g for
5 min, and serum was collected and stored at −80 °C.
Carcasses were analyzed for body composition parame-
ters using dual energy X-ray absorptiometry (GE Lunar
PIXImus; Fitchburg, WI).
The remaining 28 mice for each diet group were ran-
domly selected for subcutaneous injection (left flank)
with 5 × 104 autophagy-competent Atg5+/+;HrasV12
iBMK (Atg5+/+) cells (n = 14 mice) or autophagy-
deficient Atg5−/−;HrasV12 iBMK (Atg5−/−) cells (n = 14
mice). The respective diet regimens were continued for
the duration of the study, and tumor growth was moni-
tored for 4 weeks. Tumors were palpated and measured
with Vermeer™ calipers weekly, and tumor volume was
calculated using the formula 4/3п (r1)
2(r2). Mice were
fasted for 6 h, anesthetized with CO2 for cardiac
puncture (to obtain serum for metabolomics analysis),
and then subsequently killed by cervical dislocation.
Tumors were harvested, weighed, and either snap fro-
zen in liquid nitrogen and stored at −80 °C or em-
bedded in optimal cutting temperature compound
(OCT) and stored at −20 °C.
Blood glucose and serum energy balance-related
hormone analyses
Analysis of fasting glucose was performed on blood col-
lected at the 16-week time point using a Contour gluc-
ometer and glucose test strips (Bayer HealthCare LLC,
Mishawaka, IN). Serum insulin-like growth factor (IGF)-
1 levels were determined by ELISA (Quantikine IGF-1
ELISA kit; R&D Systems, Inc., Minneapolis, MN), ac-
cording to manufacturer’s directions. Serum levels of
insulin, leptin, and adiponectin were measured using
Lincoplex® bead-based assays (Millipore Corporation,
Billerica, MA) on a BioRad Bioplex® analyzer (BioRad,
Hercules, CA), according to manufacturer’s directions.
Metabolomic sample preparation and magnetic
resonance spectroscopy acquisition
Frozen serum samples from a random sample of 11
mice/diet group that were injected with Atg5+/+ tumor
cells at 16 weeks of study and terminated at 20 weeks of
study were deproteinized by ultrafiltration (Nanosep 3K
OMEGA, Pall Corporation, MI) at 4 °C [35, 36]. Filtered
serum was placed in 3 mm magnetic resonance spec-
troscopy (MRS) tubes (Norell, Landisville, NJ) contain-
ing phosphate buffer (final concentration 100 mM,
pH 7.0), sodium 3-(trimethylsilyl)propionate-2,2,3,3-d4
(TMSP, 0.1 mM final concentration; Cambridge Iso-
tope Laboratories, Andover MA), 0.75 % (w/v) sodium
azide and 10 % D2O (final concentration; Cambridge
Isotope Laboratories).
One-dimensional 1H-MRS spectra were acquired on
the filtered serum samples using a 700-MHz Bruker
Avance spectrometer equipped with a Bruker Triple
Resonance TCI cryoprobe and SampleXpress high-
throughput robotics (Bruker BioSpin Corp., MA). Each
sample was allowed to equilibrate for 5 min inside the
probe before starting data acquisition. The acquisition
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parameters for 1D spectra were a 90° flip angle, 6-kHz
spectral width, 1-s relaxation delay, 32,000 data points, 8
dummy scans, and 6-kHz spectral width. Excitation
sculpting pulse sequence was implemented to suppress
the water signal [37].
Histopathologic and immunohistochemical analyses
Tumors were fixed in formalin, embedded in paraffin,
cut into 4-μm thick sections, placed on glass slides (one
section/slide), and processed for either hematoxylin and
eosin (H&E) or immunohistochemical (IHC) staining.
Slides were deparaffinized in xylene and hydrated, and
antigens were retrieved by microwaving slides for
10 min with 10 mM citrate buffer. Endogenous peroxid-
ase activity was quenched by exposing slides to 3 %
hydrogen peroxide for 10 min. Following 30 min block-
ing with Biocare blocking reagent (Biocare Medical,
Concord, CA) was followed by incubation with primary
antibody diluted in the same blocking buffer as follows:
Ki-67 (Dako, Carpenteria, CA; 1:200, 4 °C overnight);
slides were washed with PBS, secondary antibody was
applied for 30 min at RT, followed by another three
washes with PBS. Diaminobenzidine (DAB) was used to
develop the antibody stain followed by a hematoxylin
counterstain to visualize nuclei. Slides were scanned and
digitized using the Aperio Scanscope System (Scanscope
XT; Aperio Technologies, Vista, CA).
Analysis of autophagy
In order to assess autophagy activation, Atg5+/+ H-Ras-
expressing iBMK cells were transfected with a GFP/RFP-
LC3 plasmid prior to implantation into nude mice. The
extent of fluorescence and number of membrane-bound
RFP-LC3 puncta per field in each tumor section was
quantified using a fluorescence microscope as previously
described [28]. For in vitro analysis of autophagic flux,
cells were incubated with 10 μM chloroquine for 24 h
before being lysed using radioimmunoprecipitation buf-
fer (RIPA), resolved by SDS-PAGE, transferred to a
PVDF membrane and probed with antibodies specific
for LC3B (Cell Signaling #2775), Atg5 (Cell Signaling
#12994), or β-Actin (Santa Cruz #).
Data analysis
Data are reported as mean ± standard error of the mean
(SEM). Comparisons between the diet groups with respect
to body composition parameters, serum markers, and
tumor weight differences were performed using t test.
Changes in tumor volume between diet groups and tumor
type were assessed using repeated measures analysis. The
proportion of mice with palpable tumors between the
autophagy-competent and autophagy-deficient tumors
was compared using Fisher’s exact test. With the excep-
tion of the MRS data, statistical analyses were conducted
using either Microsoft Excel software or STATA software
(College Station, TX). All t tests were two-tailed, and re-
sults were considered significant if p < 0.05.
All the MRS datasets were processed using MetaboLab
[38] in the MATLAB programming environment (Math-
Works, Inc., Natick, MA). MRS resonances were
assigned and the metabolites quantified using the Che-
nomx NMR Suite and other available libraries [39–42].
Principal component analysis (PCA) of 1H-MRS spectra
of serum from control and CR mice was performed
using STATA.
Results
Effects of CR on body composition parameters, blood
glucose, and serum energy balance-related hormones in
nude mice
A total of 94 female athymic nude mice were adminis-
tered either a control or CR diet, including a subset of
mice (n = 19/diet group) killed at 16 weeks on diet, in
order to analyze body composition and serum profiles.
Administration of the diet regimens for 16 weeks in-
duced two different body phenotypes in the nude mice
(Fig. 1a). Relative to the control diet-fed mice, the CR
mice weighed significantly less (p < 0.0001; Fig. 1b); had
decreased body fat and bone mineral density (p < 0.01
and p < 0.0001, respectively; Fig. 1c, e); and had greater
lean mass (p = 0.01; Fig. 1d).
CR mice displayed significantly lower levels of fasting
blood glucose (Fig. 2a), serum insulin (Fig. 2b), serum
IGF-1 (Fig. 2c), and serum leptin (Fig. 2d) than the con-
trol group, while levels of circulating adiponectin were
significantly increased by CR (Fig. 2e; n = 11 randomly
selected samples/diet group and p < 0.0001 for all
analytes).
Effect of CR and autophagy inhibition on tumor growth
Following 16 weeks of diet regimens, all remaining mice
(n = 56) were injected subcutaneously with either
autophagy-proficient Atg5+/+;HrasV12 iBMK cells or
autophagy-deficient Atg5−/−;HrasV12 iBMK cells (14
mice/cell line for each diet). These iBMK cells were de-
rived from Atg5+/+ and Atg5−/− mice, respectively. Previ-
ous studies established that deletion of Atg5 results in a
profound autophagy defect [28, 43]. Atg5 deletion and
autophagy deficiency was confirmed by western immu-
noblot analysis for Atg5 and LC3B (Fig. 3a). Unlike
Atg5+/+ cells, incubation with the lysosomal inhibitor
chloroquine does not cause accumulation of LC3B-II
in Atg5−/− cells (Fig. 3a).
As shown in Fig 3b, tumor incidence 4 weeks after
injection was significantly (p < 0.05) higher in control
diet-fed mice with Atg5+/+ tumors (12/14, 86 %) than
Atg5−/− tumors (5/14; 36 %). In CR-fed mice, Atg5+/+
tumor incidence was 71 % (10/14;) and Atg5−/− tumor
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incidence was 14 % (2/14). Tumor growth (Fig. 3c) and
final tumor volume (Fig. 3d) was greatest for Atg5+/+-
tumors in control-fed mice, intermediate for Atg5+/+-
tumors in CR-fed mice and Atg5−/− tumors in control-
fed mice, and lowest for Atg5−/− tumors in CR mice.
Tumors excised from CR groups displayed reduced
intratumoral adipocytes compared to those from control
groups (Fig 3e [i]), and both CR and autophagy defi-
ciency was sufficient to reduce proliferative (Ki67 posi-
tive) cells within the tumor (Fig 3e [ii]).
Effect of CR on autophagic flux in tumors
No diet-dependent difference in the percent of cells with
LC3 puncta was detected in tumors obtained 4 weeks
after mice were transplanted with Atg5+/+ tumor cells
(Fig. 3e). However, RFP-LC3 fluorescence was signifi-
cantly decreased in tumors from CR mice compared
with control-fed mice (Fig. 3f ). Autophagy is a highly dy-
namic process, and the flux of RFP-LC3 puncta forma-
tion and autophagosome degradation at low pH is rapid
[44]. Increased RFP-LC3 turnover due to increased
autophagic flux in response to CR likely explains the ob-
served reduction in RFP-LC3 fluorescence in the Atg5+/+
tumors from CR mice.
Effect of CR on serum metabolomic profile
The low rate of tumor development and growth pre-
cluded further in vivo analysis of the effect of CR in
Atg5−/− tumors, although previous studies have estab-
lished that LC3 puncta formation is negligible in Atg5−/−
tumors [28]. To establish a relevant in vitro approach to
study the effects of CR and/or autophagy inhibition in
Atg5−/− and Atg5+/+ cells, we first characterized the im-
pact of CR on the serum metabolomic profile using an
untargeted MRS-based metabolomics approach was
evaluated in serum samples obtained 4 weeks after mice
were transplanted with Atg5+/+ tumor cells. Figure 4a
presents representative magnetic resonance spectra.
PCA was performed on the entire MRS dataset (n = 11
serum samples per group) to evaluate the global meta-
bolic changes induced by CR relative to control (Fig. 4b);
the scores plot indicates that the serum samples from
control and CR mice are characterized by distinct meta-
bolic profiles. A further analysis of the PCA loadings
plot in conjunction with the MRS spectra profiles led to
the identification of several discriminant metabolites
that significantly change in the serum profile of CR
mice. The average serum concentration change (as per-
cent change in CR mice compared to control) of the
identified, statistically significant (p value after positive
false discovery rate correction <0.05) metabolites are
shown in Table 1 and highlighted in the MR spectra in
Fig. 5c. The serum concentrations of glucose, several
amino acids, and Krebs cycle intermediates decreased
as a consequence of CR, while ketone bodies (acetoace-
tate and 3-hydroxybutyrate in particular, and also acet-
one) increased, suggesting CR resulted in a metabolic
switch away from glucose metabolism.
Effect of glucose deprivation on colony formation
Atg5+/+ and Atg5−/− cells were grown in media with nor-
mal or reduced glucose concentrations to model in vitro
the metabolic state induced by control and CR diets in
vivo (Fig. 5). Atg5−/− cells formed fewer colonies than
Atg5+/+ in all conditions, and autophagy deficiency
(Atg5−/−) combined with low glucose (5, 1 mM) re-
sulted in significantly reduced colony formation.
Fig. 1 Effects of CR on body composition. Nude mice were fed a control or CR diet for 16 weeks (n = 19/diet group), and body size (a),
body weight (b), percent body fat (c), percent lean mass (d), and bone mineral density (e) were compared. Data presented are
the mean ± SEM
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Discussion
Our findings confirm the hypothesis that combining the
systemic metabolic reprogramming that occurs with CR
with cell intrinsic autophagy inhibition exerts more po-
tent anticancer effects in vivo and in vitro than either
CR or autophagy inhibition alone. We found that admin-
istration of a 30 % CR diet to nude mice (in which CR
has not been previously well studied) resulted in a sig-
nificant decrease in body fat, fasting blood glucose, and
serum insulin, IGF-1, and leptin levels, while it increased
adiponectin levels. Metabolomic analyses of CR-fed nude
mice showed a significant decrease in circulating glu-
cose, several amino acids (including alanine, pyruvate,
ornithine, and tyrosine), and several Krebs cycle inter-
mediates (including fumarate, 2-oxoglutamic acid) com-
pared to control mice. There was also a concomitant
increase in metabolites indicating CR induced negative
energy balance, increased fatty acid oxidation, and keto-
sis, including acetoacetate, 3-hydroxybutyrate, urea, and
acetone, consistent with a metabolic shift away from
glucose metabolism and toward fat/ketone metabolism
during CR.
To assess the separate and interactive effects of CR
and autophagy deficiency on tumor development and
growth, we used a xenograft model in nude mice sub-
cutaneously injected with iBMK cells derived from
Atg5+/+ or Atg5−/− mice, immortalized by E1A and
dominant-negative p53 expression, stably transfected
with a H-RasG12V expression construct, and a p-tFl-
RFP-tandem tagged LC3 expression plasmid [28]. CR,
relative to control diet, significantly reduced the growth of
transplanted Atg5+/+ tumors. Similar to CR, autophagy
Fig. 2 Effects of CR on blood glucose and serum energy balance-related hormones. Whole blood was collected from a subset of mice on CR or
control diet for 16 weeks and analyzed for blood glucose concentration (a). Serum levels of insulin (b), IGF-1 (c), leptin (d), and adiponectin (e)
were measured using a BioRad BioPlex analyzer. Data presented are the mean ± SEM (n = 11/diet group)
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deficiency (Atg5−/−) decreased tumor growth in control-
fed mice. Tumor growth was lowest in the combined CR
and autophagy-deficient group. Tumors derived from
mice transplanted with autophagy-competent (Atg5+/+)
cells and fed a CR diet displayed increased autophagic
flux. Despite several limitations, including the relatively
small sample size (n = 14 mice/diet group for each cell
line), the low incidence of Atg5−/− tumors, and the short-
comings associated with xenograft models for studies of
diet and cancer [20], these data illustrate three important
characteristics of energy/nutrient dependence of many tu-
mors that could inform new strategies for cancer preven-
tion and treatment. First, intracellular sources of nutrients
(autophagy) are required for efficient tumor growth. In
Fig. 3 Autophagy inhibition and CR reduce tumor growth. a Immunoblot analysis of Atg5 expression and LC3B cleavage in Atg5+/+;HrasV12 iBMK
cells or Atg5−/−;HrasV12 iBMK cells incubated with or without 10 μM chloroquine (CQ). Atg5+/+ or effect of autophagy inhibition and CR on tumor
incidence (b), tumor growth (c), and final tumor volume (d). Atg5−/− mice were transplanted into nude mice fed either a control or CR
diet (n = 14/diet and genotype), and tumor volume was measured weekly. e Representative H&E (i) and Ki67 IHC staining (ii) images of
Atg5+/+ and Atg5−/− tumors from mice fed a control or CR diet. f Effect of CR, relative to control diet, on LC3 puncta formation and RFP-
LC3 fluorescence in tumors from Atg5+/+;HrasV12 iBMK cell transplants. g Fluorescence microscopy of RFP-LC3 expressing Atg5+/+ tumor
slices from mice fed a control or CR regimen. Graphs presented are mean ± SEM and values with different letters are significantly different
at p <0.05
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addition, restriction of external substrate (via CR) signifi-
cantly prohibits tumor growth. Finally, restricting the
ability of cells to harness intracellular substrates under
conditions of limited external energy and nutrients may
have potent anticancer effects.
Metabolic reprogramming is a hallmark of tumorigen-
esis, and reduced reliance on mitochondrial respiration
and increased glycolysis are common in many cancers
[45, 46]. Associated with this so-called Warburg effect is
increased dependence on adequate levels of systemic
glucose and other substrates. In this study using metabo-
lomics profiling, we find that mice fed a CR regimen had
reduced serum levels of glucose and several amino acids.
Reduced circulating glucose and amino acids decreases
the external availability of these nutrients to the develop-
ing cancer cells, effectively starving the tumor via the
external environment. The striking increase of ketone
bodies indicates increased fatty acid breakdown as an
alternative to carbohydrate metabolism as a primary
source of energy in response to CR. As low carbohydrate/
high fat diets, which rewire energy metabolism to utilize
ketones, are effective in reducing tumor growth in a num-
ber of cancer models [47–49], our findings suggest that
the beneficial anticancer effects of both CR and ketogenic
diets may have common underlying mechanisms.
The observed suppressive effects of CR on tumor
growth in this model are consistent with several previous
studies in other cancer models [3–6, 15]. CR is known to
induce autophagy in a number of normal tissues and or-
gans [50, 51], and autophagy activation can promote sur-
vival in cancer cells during nutrient deprivation [52–55].
Our observed inhibitory effect of genetically induced au-
tophagy deficiency on tumor development and growth is
also consistent with previous reports of the anticancer ef-
fects of autophagy inhibition [23, 25–31]. However, to
date, little research has explored the potential of combin-
ing dietary (such as CR) or other interventions that induce
negative energy balance with autophagy inhibition as a
therapy in the treatment of solid tumors.
Fig. 4 Effect of CR on serum metabolomic profile. a Representative 1D 1H-MRS spectra of serum isolated from mice fed a control (n = 11) or CR
(n = 11) diet for 20 weeks and transplanted with Atg5+/+ cells. b Scores plots from principal component analysis (PCA) of 1H-MRS spectra from
control and CR serum. c Differential metabolites identified in PCA between diet groups are indicated on 1H-MRS spectra
Table 1 Effect of CR on serum metabolites
Metabolite % of control serum P value after pFDR correction
Glucose 42.0 5.5E−08
Lysine 47.2 2.4E−07
Lactate 50.8 3.1E−07
Alanine 52.0 5.53E−08
Pyruvate 57.3 5.6E−06
Tyrosine 57.7 1.07E−06
Fumarate 60.4 0.008
2-Oxoglutarate 61.9 0.023
Ornithine 66.1 0.018
Acetoacetate 842.2 4.1E−04
3-Hydroxybutyrate 500.2 4.1E−04
Urea 164.8 0.004
Acetone 152.8 0.017
Values represent the average serum concentration change (as percent change in
serum from CR mice relative to control-fed mice) of the identified, statistically
significant metabolites (Fig. 4c), based on p values after positive false discovery
rate (pFDR) correction <0.05
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One report by Harhaji et al. showed that combining
chloroquine (which inhibits autophagy by interfering
with lysosome function) with serum starvation resulted
in greater growth arrest and cell death relative to either
treatment alone in B16 melanoma cells, U251 glioma
cells, and L929 fibrosarcoma cells in vitro [56]. More-
over, consistent with our in vivo finding, Harhaji et al.
showed that autophagy inhibition (again via chloro-
quine) and a 30 % total diet restriction in vivo each slo-
wed the growth of transplanted B16 melanoma cells in
C57BL/6 mice, and combining chloroquine treatment
with the diet restriction inhibited the development and
growth of B16 melanoma better than either intervention
alone [56]. The in vivo study of B16 melanomas was
small (eight mice/treatment group), involved a 30 % total
diet restriction (which unlike a CR regimen is subject to
vitamin and mineral deficiencies) and did not include
analysis of autophagy in the tumors. Nonetheless, the
Harhaji et al. study supports our finding that combining
autophagy inhibition with CR may be an effective anti-
cancer strategy.
Although to our knowledge there are no other reports
in the literature combining CR and autophagy inhibition,
further support for this approach of combining autoph-
agy induction in cancer cells with systemic metabolic
alterations comes from a study assessing the growth of
A-2058 human melanoma cells grown in nude mice re-
ceiving a control or leucine-restricted diet, with or with-
out chloroquine treatment [57]. Chloroquine treatment
alone had a modest effect on tumor growth, while leu-
cine deprivation alone had little effect on tumor growth.
However, the combination of leucine deprivation and
chloroquine treatment strongly suppressed melanoma
growth [57].
Conclusions
In a murine model of Ras-driven cancer, combined restric-
tion of extracellular (via CR) and intracellular (via autoph-
agy inhibition) sources of energy and nutrients more
potently suppresses tumor growth than either CR or au-
tophagy inhibition alone. Similarly, glucose deprivation
combined with autophagy deficiency reduced in vitro col-
ony formation more potently than either glucose or au-
tophagy deficiency alone. Thus, interventions targeting
both systemic energy balance and tumor-cell intrinsic
autophagy may represent a potent anticancer strategy.
Current efforts in our laboratory using multiple preclinical
models of breast, colon, and pancreatic cancer focus on
elucidating the mechanisms underlying the separate and
combined effects of CR (or other forms of nutrient
deprivation) and autophagy inhibitors, including several
emerging autophagy inhibitors currently under clinical de-
velopment [58].
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